{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:01:43Z","timestamp":1766304103200,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Glob. Womens Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Disclosure of oral pre-exposure prophylaxis (PrEP) use for HIV prevention may improve adherence to PrEP; however, disclosure can be challenging and may result in stigma. Here, we describe disclosure of PrEP use among young women enrolled in a contraceptive study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this qualitative study, we conducted semi-structured, in-depth, face-to-face interviews with 13 women aged 18\u201325 years who initiated oral PrEP for HIV prevention during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. Interviews were conducted in 2021 with women from Durban, South Africa. In this analysis, we explore women's experiences of PrEP disclosure including whether they disclosed PrEP use, who they disclosed to and the reaction to disclosure, and the impact of disclosure on PrEP use. Interviews were conducted in English, audio-recorded and transcribed. Data were analysed thematically.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All women disclosed oral PrEP use to at least one individual, with some women disclosing to multiple individuals including family, friends, partners and community members. Few women did not disclose oral PrEP use to their partner due to anticipating a negative reaction from the partner, feeling that the partner would assume the woman has HIV and is taking antiretroviral therapy and fear that the partner would associate PrEP use with the woman having other partners. Reactions to oral PrEP disclosure were generally supportive or neutral, however, few women reported negative reactions that included distrust in the efficacy of PrEP to prevent HIV, discouraging the woman from using oral PrEP because of the assumption that PrEP is HIV treatment, and concern about the woman having oral PrEP side effects. Negative reactions to disclosure generally did not impact on oral PrEP use. Supportive disclosures sometimes resulted in reminders for oral PrEP dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicate that women are willing to disclose their PrEP use to at least one other person when supported. These study findings may contribute to future PrEP counselling guidelines and strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgwh.2024.1505643","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:49:27Z","timestamp":1736236167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Disclosure of oral pre-exposure prophylaxis use for HIV prevention among women enrolled in a contraceptive study: qualitative findings from Durban, South Africa"],"prefix":"10.3389","volume":"5","author":[{"given":"Ivana","family":"Beesham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mags","family":"Beksinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Milford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"year":"2015","key":"B1","article-title":"Press release: Medicines Control Council approves fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for pre-exposure prophylaxis of HIV"},{"year":"","key":"B2","article-title":"Guidelines for Expanding Combination Prevention and Treatment Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T). May 2016"},{"year":"2021","key":"B3","article-title":"2021 updated guidelines for the provision of oral pre-exposure prophylaxis (prep) to persons at substantial risk of hiv infection"},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/QAI.0000000000002927","article-title":"The effect of HIV programs in South Africa on national HIV incidence trends, 2000\u20132019","volume":"90","author":"Johnson","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.chom.2020.03.020","article-title":"PrEP for HIV prevention: evidence, global scale-up, and emerging options","volume":"27","author":"Celum","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10461-021-03455-x","article-title":"The effect of PrEP use disclosure on adherence in a cohort of adolescent girls and young women in South Africa","volume":"26","author":"Giovenco","year":"2022","journal-title":"AIDS Behav"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2349918","DOI":"10.1080\/17441692.2024.2349918","article-title":"Youth-friendly services was the magic: experiences of adolescent girls and young women in the community PrEP study, South Africa","volume":"19","author":"Mudzingwa","year":"2024","journal-title":"Glob Public Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0292529","DOI":"10.1371\/journal.pone.0292529","article-title":"Family influences on oral PrEP use among adolescent girls and young women in Kenya and South Africa","volume":"18","author":"Ndimande-Khoza","year":"2023","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1206075","DOI":"10.3389\/frph.2023.1206075","article-title":"Male partners\u2019 support and influence on pregnant women\u2019s oral PrEP use and adherence in Malawi","volume":"5","author":"Young","year":"2023","journal-title":"Front Reprod Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0248307","DOI":"10.1371\/journal.pone.0248307","article-title":"Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence","volume":"16","author":"Giovenco","year":"2021","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1007\/s10461-023-04109-w","article-title":"Adolescent girls and young women\u2019s experiences with disclosing oral PrEP or dapivirine vaginal ring use: a multi-country qualitative analysis","volume":"27","author":"Young","year":"2023","journal-title":"AIDS Behav"},{"key":"B12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(19)31288-7","article-title":"HIV Incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.12688\/gatesopenres.12775.1","article-title":"Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study)","volume":"1","author":"Hofmeyr","year":"2017","journal-title":"Gates Open Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e25491","DOI":"10.1002\/jia2.25491","article-title":"Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial","volume":"23","author":"Beesham","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s12889-023-16139-z","article-title":"Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa","volume":"23","author":"Beesham","year":"2023","journal-title":"BMC Public Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4212\/cjhp.v68i3.1456","article-title":"Qualitative research: data collection, analysis, and management","volume":"68","author":"Sutton","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s10461-023-04175-0","article-title":"The effect of disclosure of PrEP use on adherence among African young women in an open-label PrEP study: findings from HPTN 082","volume":"28","author":"Beauchamp","year":"2024","journal-title":"AIDS Behav"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s10461-022-03652-2","article-title":"Barriers to oral HIV Pre-exposure prophylaxis (PrEP) adherence among pregnant and post-partum women from Cape Town, South Africa","volume":"26","author":"Beesham","year":"2022","journal-title":"AIDS Behav"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e26175","DOI":"10.1002\/jia2.26175","article-title":"Factors that influence adolescent girls and young women\u2019s re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from eastern Cape province, South Africa","volume":"26","author":"de Vos","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e25463","DOI":"10.1002\/jia2.25463","article-title":"The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study","volume":"23","author":"Velloza","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0258542","DOI":"10.1371\/journal.pone.0258542","article-title":"Adolescent girls and young women\u2019s PrEP-user journey during an implementation science study in South Africa and Kenya","volume":"16","author":"Rousseau","year":"2021","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12879-022-07376-5","article-title":"Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe","volume":"22","author":"Skovdal","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2989\/16085906.2023.2169177","article-title":"Key stakeholders\u2019 perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa","volume":"22","author":"Beesham","year":"2023","journal-title":"Afr J AIDS Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"}],"container-title":["Frontiers in Global Women's Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2024.1505643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:49:30Z","timestamp":1736236170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2024.1505643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":27,"alternative-id":["10.3389\/fgwh.2024.1505643"],"URL":"https:\/\/doi.org\/10.3389\/fgwh.2024.1505643","relation":{},"ISSN":["2673-5059"],"issn-type":[{"type":"electronic","value":"2673-5059"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1505643"}}